The anti-proliferative action of the seco-steroid hormone 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D 3 ] extends to some, but not all breast and prostate cancer cell lines. By elucidating the molecular mechanisms mediating the sensitivity of these cells, we can identify critical target genes regulated directly or indirectly by 1a,25(OH) 2 D 3 and pathways potentially disrupted during transformation. In this study, we demonstrated the induction of expression of BRCA1 mRNA and protein as well as transcriptional activation from the BRCA1-promoter by 1a,25(OH) 2 D 3 in the sensitive breast cancer cell line MCF-7. This was not observed in the 1a,25(OH) 2 D 3 -resistant breast cancer cell line MDA-MB-436. The induction of BRCA1 mRNA was blocked by cyclohexamide. This indicated that transcriptional activation was mediated indirectly by the vitamin D receptor (VDR). Inhibition of VDR protein levels by stable transformation of the anti-sense VDR in MCF-7 reduced the sensitivity of MCF-7 to 1a,25(OH) 2 D 3 by 50-fold. In addition, the induction of BRCA1 protein and transcriptional activation of a BRCA1 promoter-luciferase reporter construct was abrogated in the stable transformant with the greatest reduction of VDR levels. Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative eects of 1a,25(OH) 2 D 3 was strongly associated with an ability to modulate BRCA1 protein. Furthermore, the expression of the estrogen receptor in these cell lines strongly correlated with their sensitivity to 1a,25(OH) 2 D 3 and their ability to modulate BRCA1 expression. Taken together, our data support a model whereby the anti-proliferative eects of 1a,25(OH) 2 D 3 are mediated, in part, by the induction of BRCA1 gene expression via transcriptional activation by factors induced by the VDR and that this pathway is disrupted during the development of prostate and breast cancers.
Introduction
The ligand for the vitamin D 3 receptor (VDR), 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D 3 ], was described classically for its role in calcium metabolism, but subsequent studies demonstrated its ability to inhibit growth and induce dierentiation in a variety of cancer cells including myeloid, breast and prostate (Colston et al., 1981; Munker et al., 1986; Elstner et al., 1995; Campbell et al., 1997a) . One established 1a,25(OH) 2 D 3 -target gene that mediated these eects is the CDKI p21 (waf1/cip1) . Up-regulation of this gene results in cell cycle arrest and induction of dierentiation (Schwaller et al., 1993; Liu et al., 1996) . Despite extensive eorts devoted to identifying changes in gene expression that mediate the anti-proliferative action of 1a,25(OH) 2 D 3 , why cancer cells derived from the same tissue type demonstrate a wide range of sensitivities remains unclear. For example, MCF-7 breast cancer cells and LNCaP prostate cancer cells display acute sensitivity to the growth inhibitory eects of 1a,25(OH) 2 D 3 at nM concentrations. On the other hand, MDA-MB-436 breast cancer cells and DU-145 prostate cancer cells are relatively resistant requiring concentrations of greater than 1 mM to inhibit cell or colony growth by more than 50% (Elstner et al., 1995; Campbell et al., 1997a) . Intriguingly, 1a,25(OH) 2 D 3 -resistant cancer cell lines retain wild-type expression of the VDR in a transcriptionally active form; therefore, lack of a functional VDR cannot explain resistance (Miller et al., 1992 (Miller et al., , 1995 Zhang et al., 1997) . Undoubtedly, the loss of function or regulation of critical downstream, target genes may contribute to 1a, 25(OH) 2 D 3 -resistance. For example, DU-145 is androgen-independent and has mutations in cell cycle regulatory genes (Gaddipati et al., 1994; Carrol et al., 1993; Tamimi et al., 1996; Issacs et al., 1994) . Also, evidence is accumulating that during transformation, selective transcriptional silencing occurs in genes that are important for the inhibitory action of 1a,25(OH) 2 D 3 . For example, we showed that p21 (waf1/cip1) protein is less readily induced in DU-145 than LNCaP cells (Campbell et al., 1997a) , whereas another 1a,25(OH) 2 D 3 -responsive gene, the cytochrome p450 enzyme 1a,25(OH) 2 D 3 -24-hydroxylase, is signi®-cantly more up-regulated in DU-145 than LNCaP (Miller et al., 1992) .
The presence of highly recalcitrant cancer cells has limited the therapeutic applications of 1a,25(OH) 2 D 3 because of the hypercalcemic side eects associated with the high, pharmacologically active doses required to inhibit the growth of these cells. To increase the therapeutic potential of 1a,25(OH) 2 D 3 , we and others are examining the mechanism of action of 1a,25(OH) 2 D 3 to highlight novel therapeutic opportunities. Several aspects of this research include investigation of potent vitamin D 3 analogues, such as the 20-epi and 19-nor hexa¯uoride compounds that possess increased growth inhibitory eects over the parental hormone (Elstner et al., 1995; Campbell et al., 1997a; Asou et al., 1998) and identifying genes that impart 1a,25(OH) 2 D 3 sensitivity to a cell.
In this study we present evidence that the gene encoding breast cancer susceptibility protein, BRCA1, is a critical downstream target of 1a,25(OH) 2 D 3 . The BRCA1 gene is mutated in families with a high incidence of inherited breast and ovarian cancers Miki et al., 1994) and probably prostate cancer (Arason et al., 1993; Gao et al., 1995; Marakami et al., 1995; Langston et al., 1996) . BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive breast cancer in sporadic cases (Thompson et al., 1995) . Its exact function(s) remains unclear, although it can act as a transcription factor (Monteiro et al., 1996) associates with p53 (Zhang et al., 1998) and plays a role in cell cycle regulation by regulating DNA repair and apoptosis (Runer and Verma, 1997; Scully et al., 1997) . Transfection studies with BRCA1 in MCF-7 breast cancer cells revealed its ability to control cell growth in vivo (Holt et al., 1996) . Previously, we showed that BRCA1 protein expression increased in MCF-7 cells after treatment with the analogue 1a,25(OH) 2 -20-epi-D 3 (Campbell et al., 1997b) . In this study, we investigated the mechanism of induction of BRCA1 by 1a,25(OH) 2 D 3 and how it may be disrupted in malignancy.
Results

Modulation of BRCA1 protein and RNA expression in MCF-7 breast cancer cells
We initially investigated the modulation of BRCA1 protein expression by 1a,25(OH) 2 D 3 in MCF-7 breast cancer cells. The level of BRCA1 protein increased in MCF-7 cells treated with 1a,25(OH) 2 D 3 . By day 3, a 5.7-fold increase in protein expression occurred compared to the untreated control (day 0). The levels of BRCA1 decreased slightly to 4.6-fold by day 5 (Figure 1a ). Previous workers, using this antibody, have also reported cross-reactivity to dierent migrating species, similar to those detected here (Gudas et al., 1995) .
To determine if the increase in BRCA1 protein levels corresponded with an increase in mRNA levels, we performed Northern blot analysis on MCF-7 cells treated with 1a,25(OH) 2 D 3 . We detected two mRNA transcripts, the principal transcript was approximately 8.0 kb and increased to a maximum of 2.3-fold after 1 day exposure to 1a,25(OH) 2 D 3 ( Figure 1B) ; the other transcript was approximately 4.0 kb and was only signi®cantly up-regulated after 2 days exposure to 1a,25(OH) 2 D 3 . Previous studies have reported similar multiple transcripts (Gudas et al., 1995) . The induction of BRCA1 mRNA levels was inhibited by the presence of cyclohexamide indicating that protein synthesis was required (Figure 2 ). These results suggest that the increase in BRCA1 protein levels are due, in part, to increased transcription of the gene indirectly mediated by vitamin D and its receptor.
Reduced VDR expression abrogates 1a,25(OH) 2 D 3 -mediated inhibition of growth and expression of BRCA1 protein
To determine the role of the VDR in mediating the eect of growth inhibition and induction of BRCA1 gene expression, we generated MCF-7 cell lines stably expressing anti-sense VDR. To con®rm the correct identi®cation of the VDR band in our stable transfectants we transfected COS-1 cells with an empty (7) or presence (+) of CHX (20 mg/ml). Expression of BRCA1 was determined by Northern blot analysis and integrity and loading of the RNA was determined by hybridization with a probe to b-actin pcDNA1 vector and a construct with the human VDR (hVDR) inserted into the expression site ( Figure 3a ). Densitometric analysis of multiple blots of the two clones generated, MCF-7 AS2 and MCF-7 AS4, revealed they had a mean 55% and 80% less expression of VDR compared to the empty-vector control (MCF-7 Neo).
To assess the eects of reduced VDR levels on induction of BRCA1 both MCF-7 Neo and MCF-7 AS4 were treated with 1a,25(OH) 2 D 3 for 48 h. The MCF-7 AS4 showed similar basal levels of BRCA1 expression to the control but the ability to induce expression was abrogated (Figure 3b ). Densitometric analysis revealed that after 48 h exposure the induction of BRCA1 expression in the control (MCF-7 Neo) was equal to that observed in the wild-type cells (approximately threefold). However, expression of BRCA1 in the MCF-7 AS4 line did not signi®cantly increase over that of the untreated cells (1.1-fold). Previously, we demonstrated the anti-proliferative eects of 1a,25(OH) 2 D 3 on wild-type MCF-7 in a clonal proliferation assay (Elstner et al., 1995) . We utilized this assay to measure the dose-dependent inhibition of clonal proliferation by 1a,25(OH) 2 D 3 of the control and anti-sense VDR stable lines. Figure 3c shows that the signi®cant reduction in sensitivity to anti-proliferative eects of 1a,25(OH) 2 D 3 directly correlated with the level of VDR expression and a reduced ability to modulate BCRA1. MCF-7 Neo, with the wild-type level of VDR expression was most sensitive and MCF-7 AS4, with the lowest levels of VDR expression was least sensitive to clonal inhibition by 1a,25(OH) 2 D 3 . For MCF-7 AS4, the estimated dose of 1a,25(OH) 2 D 3 required to inhibit clonal growth by 50% (ED 50 ) increased from 20 to 4100 nM (P50.01). For MCF-7 AS2, with intermediate VDR expression, the ED 50 only increased to 100 nM for 1a,25(OH) 2 D 3 (P50.05) (P50.05) ( Figure 3b and Table 1 ). Together these results indicate that both growth suppression and the concomitant induction of BRCA1 protein by 1a,25(OH) 2 D 3 treatment is mediated via the VDR.
Modulation of BRCA1 protein expression in breast and prostate cancer cell lines
We further examined the signi®cance of BRCA1 regulation by 1a,25(OH) 2 D 3 in a panel of prostate and breast cancer cell lines that are either sensitive or resistant to the anti-proliferative eects of 1a,25(OH) 2 D 3 . The levels of BRCA1 protein expression increased in the three sensitive cell lines MCF-7, LNCaP and PC-3. However in the cell lines, BT-20, MDA-MB-231, MDA-MB-436, DU-145 and TSU-PR-1, that are essentially resistant [ED 50 is equal to or greater than 1000 nM 1,25(OH) 2 D 3 ] (Elstner et al., 1995; Campbell et al., 1997a; Asou et al., 1998 and Campbell MJ, unpublished observation) , BRCA1 expression was not up-regulated in response to 1a,25(OH) 2 D 3 ( Figure 4 and Table 1 ). Interestingly, only those cell lines that were ER-positive displayed 1a,25(OH) 2 D 3 -induced BRCA1 expression. Both MDA-MB-231 and MDA-MB-436 are ER-negative and do not express detectable basal or induced levels of BRCA1. Previously, we were unable to detect ER expression, by immuno¯uorescence, in BT-20 cells (Elstner et al., 1995) although, a weak signal for an alternatively spliced mRNA was detected by others (Fasco, 1998; Leygue et al., 1999 (Figure 4 and Table  1 ). These data suggest that sensitivity of breast and Figure 5 ). These results support further the concept that BRCA1 induction involves multiple mechanisms of control. Separately the VDR and the ER signalling axis can modulate its expression, but in the most aggressive, hormonally insensitive cell lines, neither pathway is able to transactivate the promoter.
Discussion
Previous studies examining the steroid hormone regulation of BRCA1 gene transcription revealed that it was dependent upon ER expression although the eects were modest (Xu et al., 1997; Gudas et al., 1995) . In this study, we demonstrated that 1a,25(OH) 2 D 3 enhanced expression of BRCA1 protein and mRNA and enhanced transcriptional activation of a BRCA1 promoter-reporter construct. The up-regulation of BRCA1 mRNA was blocked by cyclohexamide and in cells with reduced VDR levels; therefore, we concluded that the mechanism of 1a,25(OH) 2 D 3 -dependent regulation of BRCA1 involved direct binding of a transcriptional factor(s) to a cis-regulatory element in the BRCA1 promoter that was induced by 1a,25(OH) 2 D 3 and its receptor. The indirect VDRmediated induction of BRCA1 is closely correlated with the anti-proliferative action of 1a,25(OH) 2 D 3 in breast and prostate cancer cells. This is particularly evident in the antisense VDR stably-expressing cell line, MCF-7 AS4, that is resistant to 1a,25(OH) 2 D 3 and displays abrogated induction of BRCA1 protein.
Interestingly, our study indicated a role for crosstalk between the ER and the VDR in mediating the induction of BRCA1 suggesting a possible important interaction between these two receptors. Similarly, a Elstner et al. (1995) ; c Clonal growth in the presence or absence of vitamin D 3 analogues was examined using a two-layer soft-agar colony assay. Each experimental point represents the mean of three dishes and was repeated in triplicate. After 14 days, colonies were counted and expressed as a percentage of the colonies in untreated control. These data were used to construct dose-response curves (each curve generated from a set of triplicate experiments) and ED 50 dose (nM) was interpolated from the curve. Figure 4 Regulation of BRCA1 protein in a MCF-7, BT-474, MDA-MB-436 breast and LNCaP, TSU-Pr-1 prostate cancer cell lines. Cells were exposed to 1a,25(OH) 2 D 3 (+, 100 nM) or untreated (7) and total protein was isolated on day 2 of treatment. Expression of BRCA1 was determined by Western blot analysis. The position of BRCA1 is indicated at the right of the panel number of other studies have suggested an interaction between these two receptors. Murine knockout and physiological studies demonstrated that both the VDR and ER play critical roles in the growth and dierentiation of a number of tissues including mammary glands and the reproductive tract (Korach et al., 1994) . For example, the VDR knockout mouse displays critical growth defects in the female reproductive organs, speci®cally hypoplasia of the uterus, partly attributable to a lack of estrogen production, thus further supporting a role for VDR in the regulation of estrogenic events (Yoshizawa et al., 1997) . Similarly, speci®c VDR and ER polymorphisms are linked to bone mineral density in postmenopausal women (Gennari et al., 1998; Deng et al., 1998) and to the regulation of infant growth (Suarez et al., 1998) . Also, VDR polymorphisms are associated with increased risk for prostate cancer and the progression of breast cancer, possible as a result of altered transcriptional activity (Ingles et al., 1997; Lundin et al., 1999; Jurutka et al., 2000) . In addition, most recently, BRCA1 was found to inhibit ERdependent transcriptional pathways, thereby suggesting a mechanism for BRCA1 to suppress proliferation of estrogen-dependent mammary epithelial cells (Fan et al., 1999) . Taken together, these studies support a critical role for BRCA1 in the integration of diverse signals, such as those mediated by the VDR and ER, to promote proliferation in a controlled manner.
The mechanism for the cooperativity between these two receptors is unclear. Our data suggest that a VDRdependent downstream eecter initiates BRCA1 transcription. Gene promoter regions often contain multiple response elements that may synergize together directly or by virtue of maintaining promoter-associated histones in an acetylated state thereby sustaining a transcriptionally active form. The data in this study suggest a co-dependence on both VDR and ER to facilitate expression and modulation of BRCA1. This may re¯ect the binding of transcriptional factors that are induced by both 1a,25(OH) 2 D 3 and estrogen to the promoter region of the BRCA1 gene. The identity of these factors is currently unknown. Similarly regulation of p27 (kip1) by 1a,25(OH) 2 D 3 has been shown to be an indirect, post-transcriptional mechanism [Hengst and Reed 1996] .
We propose a model whereby VDR and ER signalling pathways converge on the regulation of BRCA1 to allow a balance between growth and dierentiation, a process that is corrupted in more aggressive breast and prostate cancer cell lines. A similar interaction between divergent signalling pathways has been observed between 1a,25(OH) 2 D 3 and testosterone to control dierentiation of the normal prostate gland (Konety et al., 1996) . The recent cloning and characterization of the alternative ERb receptor (Mosselman et al., 1997) and its splice variants revealed that cancer cells express a dierent ratio of receptors compared to their non-transformed counterparts (Leygue et al., 1999; Vladusic et al., 1998) . The expression patterns may further manipulate 17b estradiol signalling such as to enhance the proproliferative aspects of signalling at the expense of those associated with dierentiation. Quite possibly, regulation of BRCA1 gene expression may be one aspect of this signalling pathway that is altered. We, therefore, conclude that regulation of expression of BRCA1 plays a role in the anti-proliferative action of 1a,25(OH) 2 D 3 in a complex process involving both VDR and ER expression.
Materials and methods
Cell lines and cell culture
Cell lines were obtained from ATCC (Rockville, MD, USA). LNCaP, TSU-PR-1, BR-20, BT-474 were maintained in RPMI 1640 with 10% FCS; PC-3, DU-145, MCF-7, MDA-MB-231, MDA-MB-436, were maintained in DMEM with 10% FCS (GIBCO/BRL, Grand Island, NY, USA).
Vitamin D 3 and analogues
The 1a,25(OH) 2 D 3 (compound C) and its analogue IE (a kind gift from Dr Milan R Uskokovic, Homan-La Roche, Nutley, NJ, USA) were prepared as stock solutions in ethanol at a concentration of 1.0 mM and stored at 7208C in the dark. For experimental use, the compounds were diluted in normal media.
Western immunoblot analysis
Whole cell lysates were prepared and Western blot analysis performed as described previously (Gombart et al., 1997) . Brie¯y, 30 mg of total protein for each sample was electrophoresed through an SDS-polyacrylamide gel, transferred onto a PVDF membrane (Immobilon-P; Millipore, Bedford, MA, USA) and blocked with Tris-buered saline Tween 20, (0.1%) (pH 7.5) containing 2.5% milk powder for 1 h. For detection of BRCA1, a rabbit polyclonal antibody against human BRCA1 (Clone C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was diluted 1 : 4000. For detection of hVDR, a rat monoclonal against hVDR was diluted 1 : 2000 (Chemicon International, Inc., Temecula, Figure 5 Transactivation of a full-length BRCA1 promoterluciferase reporter construct is abrogated in VDR-antisense expressing cells. MCF-7, MCF-7 Neo, MCF-7 AS4 and MDA-MB-231 cells were transfected transiently with the BRCA1 reporter construct, pGL1, and either exposed to 1a,25(OH) 2 D 3 (D 3 , 100 nM), 17b estradiol (E 2 , 10 nM, positive control) or untreated (negative control). Luciferase activity was measured and normalized to total protein. Each experiment was performed in duplicate wells at least three times to determine the mean fold increase (+s.e.m) in transactivation over untreated cells. MCF-7-neo cells (not shown) did not signi®cantly dier from MCF-7 cells. *=P50.005, **=P50.01 CA, USA). Positive and negative controls for hVDR were prepared by transfection of COS-1 cells with pcDNAIhVDR-S and pcDNAI, respectively. The secondary antibodies donkey anti-rabbit-HRP conjugate (Amersham Life Sciences, Amersham, UK) and rabbit anti-rat-HRP (Sigma) were diluted 1 : 3000 and 1 : 50,000, respectively. The proteins were detected using the ECL system (Amersham Life Sciences). To ensure even loading of protein, the nonspeci®c, background bands were compared or the membranes were stained with Ponceau S. To quantify the relative changes in the protein levels, densitometry was performed on autoradiographs using the AlphaInotech gel documentation system (AlphaInotech, San Francisco, CA, USA).
RNA isolation and Northern blot analysis
Total RNA was prepared from wild-type MCF-7 cells exposed to 1a,25(OH) 2 D 3 for speci®ed periods of time by extraction with TRIZOL reagent (GIBCO/BRL). Cyclohexamide was used at a ®nal concentration of 20 mg/ml. Approximately 30 mg of RNA was electrophoresed on formaldehyde agarose gels, transferred to Hybond-N+ membrane (Amersham Life Sciences), and hybridized with a 32 P-labelled BRCA1 probe. Ethidium bromide stained gels were photographed prior to transfer to membrane to ensure balanced loading of samples.
The BRCA1 probe was a 710 bp PCR fragment representing bases 333 ± 1043 ampli®ed with the following primers; forward (5' to 3') AGC CTA CAA GAA AGT ACG AGAT and reverse (5' to 3') TGC TTT TAT TAC AGA ATT CAG CCT, from cDNA prepared from MCF-7 total RNA. For each reaction, 2 ml of template was mixed with 100 mM TrisHCl, pH 9.0, 500 mM KCl, 5 mM MgCl 2 , 0.2 mM dNTPs, 0.3 mM primer, and 1.5 U TAQ polymerase (Promega Life Sciences, Madison, WI, USA) in a ®nal volume of 30 ml. The mixture was overlaid with mineral oil and ampli®ed in a thermal cycler as follows: 948C for 1 min, 558C for 36 s, 728C for 36 s for 35 cycles, then a ®nal extension at 728C for 7 min.
Construction of anti-sense VDR expression vector and generation of stable transformants
The cDNA encoding the human VDR (Baker et al., 1988) , a kind gift from Dr Wesley Pike, was subcloned from pGEM3Z using EcoR1 into an eukaryotic expression vector, pcDNAI, digested with EcoR1 (Invitrogen, Carlsbad, CA, USA). A clone containing the cDNA in the antisense orientation with respect to the CMV promoter was isolated.
MCF-7 cells were transfected using the calcium phosphate method (Gombart et al., 1997) . Approximately 1610 6 cells were transfected with 8 mg of either pcDNAI-hVDR-AS or pcDNAI and 2 mg of pCMV-Neo. Two days post-transfection, cells were split into medium containing G418 (500 mg/ ml). Medium containing G418 was changed every 4 days. After 2 weeks of selection, six individual colonies were isolated and subcultured in 24-well plates. The clones were ampli®ed, frozen and examined for VDR expression by Western blot analysis. Three stable cell lines were used in this study: (i) MCF-7 Neo, empty vector control; (ii) MCF-7 AS2, a cell line with intermediate levels of VDR expression and (iii) MCF-7 AS4, a cell line with the lowest level of VDR expression.
Colony formation in soft agar
Single-cell suspensions from either wild-type MCF-7, MCF-7 Neo or two stable anti-sense VDR expressing cell lines, MCF-7 AS2 and MCF-7 AS4, were prepared from 80% con¯uent cultures. The cells were counted and plated onto 24-well¯at-bottomed plates using a two-layer soft agar system with 1610 3 cells in 400 ml of media per well, as described previously (Campbell et al., 1997b) . The feeder layer was prepared with agar (1%) equilibrated at 428C. Prior to addition of this layer to the plate, 1a,25(OH) 2 D 3 , or vitamin D 3 analogue, IE, and G418 (300 mg/ul) were pipetted into the wells. Stock solutions of 1a,25(OH) 2 D 3 and IE and experimental plates were kept in the dark to reduce UVcatalysed degradation. After 14 days of incubation, the colonies (450 cells) were counted using an inverted microscope. All experiments were done at least three times in triplicate per experimental point and all statistical analyses were performed using the Student's t-test.
Analysis of BRCA1 promoter activation
The plasmid pGL1, a kind gift from Dr C-F Xu (Guy's Hospital, London), contains the full length BRCA1 promoter and was used previously to characterize the BRCA1 promoter (Gudas et al., 1995) . Wild-type MCF-7 cells, MCF-7 Neo cells, MCF-7 AS4 and MDA-MB-231 cells (1.5610 5 /well) were plated into normal media (MCF-7 and MDA-MB-231) or media plus G418 (500 mg/ul) (stable transformants) and allowed to adhere overnight. Prior to transfection the cells were washed in serum-free Opti-MEM (GIBCO/BRL). Transfection with Lipofectamine (GIBCO/ BRL) was optimized according to manufacturer's instructions. The reporter plasmid pGL1 (1.5 mg/well) was mixed in a 10 : 1 ratio with Lipofectamine in 1.5 ml of Opti-MEM and incubated with the cells for 18 h. An equal volume of RPMI containing 20% charcoal-stripped FCS was added to each well and the cells were cultured for an additional 24 h in the presence of 1a,25(OH) 2 D 3 (100 nM), 17b estradiol (10 nM) (positive control) or left untreated (negative control).
The luciferase activity was measured in cell lysates using the Luciferase Assay System according to the manufacturer's instructions (Promega Life Sciences). The luciferase activity was normalized to total protein for each sample and compared to reporter gene activity in the absence of either 1a,25(OH) 2 D 3 or 17b estradiol. All experiments were performed in duplicate wells at least three times and all statistical analyses was performed using the Student's t-test.
Abbreviations VDR, vitamin D 3 receptor; ER, estrogen receptor; VDRE, vitamin D 3 receptor enhancer; RARE, retinoic acid receptor enhancer; 1a,25(OH) 2 D 3 , 1a,25-dihydroxyvitamin D 3 ; IE, 1a,25-(OH) 2 -20-epi-D 3 ; CDKI, cyclin-dependent kinase inhibitor; CHX, cyclohexamide.
